Collegium Pharmaceutical (NASDAQ:COLL - Free Report) had its price target lowered by Piper Sandler from $37.00 to $36.00 in a research report report published on Tuesday,Benzinga reports. The firm currently has a neutral rating on the specialty pharmaceutical company's stock.
A number of other equities research analysts have also recently commented on the company. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, October 23rd. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 target price for the company in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of "Moderate Buy" and an average target price of $43.60.
View Our Latest Stock Report on COLL
Collegium Pharmaceutical Stock Down 0.4 %
NASDAQ:COLL traded down $0.13 during midday trading on Tuesday, reaching $30.82. 261,433 shares of the stock traded hands, compared to its average volume of 416,941. The business has a 50-day moving average of $31.03 and a two-hundred day moving average of $34.11. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical has a 12-month low of $28.39 and a 12-month high of $42.29. The stock has a market capitalization of $993.95 million, a PE ratio of 13.28 and a beta of 0.82.
Insider Activity at Collegium Pharmaceutical
In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business's stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. The trade was a 18.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 3.98% of the company's stock.
Institutional Trading of Collegium Pharmaceutical
Several institutional investors have recently modified their holdings of COLL. GAMMA Investing LLC grew its stake in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company's stock worth $55,000 after buying an additional 792 shares during the last quarter. CWM LLC grew its position in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company's stock worth $58,000 after acquiring an additional 736 shares during the last quarter. TD Private Client Wealth LLC increased its holdings in shares of Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock valued at $66,000 after acquiring an additional 483 shares during the period. KBC Group NV raised its position in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after purchasing an additional 982 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after purchasing an additional 316 shares during the period.
Collegium Pharmaceutical Company Profile
(
Get Free Report)
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Featured Stories
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
